跳至主要内容
临床试验/ACTRN12609000399291
ACTRN12609000399291已完成2 期

Patients with bone marrow oedema-associated knee pain, randomised to zolendronic acid or placebo, assessed by the amount of knee pain after three and twelve months.

Menzies Research Institue0 个研究点目标入组 60 人开始时间: 2009年6月2日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 100 Years(—)
性别
All

入选标准

  • Knee Pain with bone marrow oedema on magnetic resonance imaging (MRI).

排除标准

  • Any prior use of bisphosphonate preparations, except according to the washout schedule:
  • 2 years (if use >48 weeks)
  • 1 year (if used >8 weeks but <48 weeks)
  • 6 months (if used >2 weeks but <8 weeks)
  • 2 months (if used <2 weeks)
  • Any intravenous bisphosphonate within the prior 2 years,
  • History of iritis or uveitis, except due to trauma, and resolved for >2 years prior to study
  • Serum calcium >2.75 mmol/L (11.0 mg/dL) or <2.00 mmol/L (8.0 mg/dL)
  • Serum 25-hydroxyvitamin D concentrations <15 ng/L
  • Use of any investigational drug(s) and/or devices within 30 days prior to randomization
  • creatinine clearance < 35 ml/min
  • Metastatic cancer or cancer diagnosed less than 2 years ago where treatment is still ongoing
  • A dental exam with appropriate preventative dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, corticosteroids, poor hygiene)

研究者

发起方
Menzies Research Institue

相似试验